Novartis Zometa label update
Novartis updates labeling for its oncologic Zometa to include a precaution for osteonecrosis of the jaw. The precaution recommends that a dental examination with appropriate preventive dentistry be considered prior to beginning therapy in patients with concomitant risk factors (e.g. cancer, chemotherapy, corticosteroids, poor oral hygene). Novartis informed physicians of the Zometa (zoledronic acid) label change in a Sept. 24 "Dear Doctor" letter; the labeling changes were also made to Novartis' Zometa precursor Aredia...
You may also be interested in...
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.